$ILMN

Illumina appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to the company. Sullivan will lead global commercial operations; Coletti will oversee legal, regulatory, and government affairs and serve as corporate secretary. The article also notes expanded Illumina-Labcorp oncology testing collaboration and a new cloud multiomics software platform.

Meister Keith A. sold 741,127 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $199.91 ($196.74–$203.28, $148.16M total) across 14 trades over 2026-08-04 to 2026-08-05.

Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.

Illumina, Inc. (NASDAQ: ILMN) appointed Mike Sullivan as Chief Commercial Officer effective July 20, 2026, and Julie Coletti as Chief Legal Officer effective August 3, 2026. Sullivan will lead the global commercial organization, previously serving as CCO at Caris Life Sciences. Coletti will oversee legal, regulatory and government affairs, previously serving as Chief Legal and Regulatory Officer at Align Technology.

Bernstein SocGen analyst Eve Burstein resumed coverage of Illumina (ILMN) with a Market Perform rating and $185 price target. She cited early-2025 China restrictions on Illumina instruments and inclusion on an Unreliable Entities List as weighing on revenue estimates, but said NovaSeq X and expanding clinical applications supported a recovery amid improving life-science funding and drug trial activity.

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ilmn-20260616 0001110803 FALSE June 16, 2026 0001110803 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest ev